Jia-Yi Wu - the Shengli Clinical Medical College, Fujian Medical University

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 45 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Combination Therapy Consisting of Transarterial Chemoembolization, Lenvatinib, and Programmed Cell Death Protein 1 Blockade for Hepatocellular Carcinoma with Inferior Vena Cava Tumor Thrombus: a Case Series Study and Literature Review

Yang-Kai Fu,Yi-Nan Li, De-Yi Liu,Zhen-Xin Zeng,Jia-Yi Wu,Jun-Yi Wu, Jin-Xiu Wang,Han Li, Xiang-Ye Ou,Mao-Lin Yan

Oncology research and treatmentno. 10 (2024): 465-473

引用0浏览0WOS引用

Long-term Surgical Outcomes of Bile Duct Tumor Thrombus Versus Portal Vein Tumor Thrombus for Hepatocellular Carcinoma: a Propensity Score Matching Analysis

Yi-Nan Li, Shao-Ming Wei,Yang-Kai Fu,Zhen-Xin Zeng,Li-Ming Huang,Jia-Hui Lv,Wei-Zhao Chen,Yong-Gang Wei,Zhi-Bo Zhang,Jian-Yin Zhou,Jia-Yi Wu,Mao-Lin Yan

Frontiers in Oncology (2024)

引用0浏览0WOS引用

Perioperative Lenvatinib Combined with Tislelizumab Plus Transcatheter Arterial Chemoembolization in Resectable Hepatocellular Carcinoma with High-Risk of Recurrence: A Prospective, Single-Arm, Phase 2 Trial

Jia-Yi Wu,Yang-Kai Fu,Tianfu Wen,Shuang-Jia Wang, Jiafei Chen,Zhibo Zhang, Chongyuan Liu,Wei Wang,Lu Fang, Zhong Tang,Yufeng Chen,Maolin Yan

JOURNAL OF CLINICAL ONCOLOGY（2024）

引用0浏览0引用

Salvage Surgery for Initially Unresectable HCC with PVTT Converted by Locoregional Treatment Plus Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody

Lei Wang,Jin-Kai Feng,Chong-De Lu,Jia-Yi Wu, Bin Zhou,Kang Wang,Xu-Biao Wei,Chao Liang,Hong-Kun Zhou,Jie Shi,Wei-Xing Guo,Wan Yee Lau,Mao-Lin Yan,Shu-Qun Cheng

ONCOLOGISTno. 8 (2024): e1041-e1050

引用0浏览0WOS引用

Efficacy of Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Retrospective, Multicenter Study

Xiangye Ou,Junyi Wu,Jiayi Wu,Yangkai Fu,Zhenxin Zeng,Shuqun Li,Yinan Li,Deyi Liu,Han Li,Bin Li,Jianyin Zhou,Shaowu Zhuang,Shuqun Cheng,Zhibo Zhang,Kai Wang,Shuang Qu,Maolin Yan

Cancer research and treatmentno. 4 (2024): 1207-1218

引用0浏览0WOS引用

Prognostic Value of Pathological Response for Patients with Unresectable Hepatocellular Carcinoma Undergoing Conversion Surgery

Zhen-Xin Zeng,Jia-Yi Wu,Jun-Yi Wu,Zhi-Bo Zhang,Kai Wang,Shao-Wu Zhuang,Bin Li,Jian-Yin Zhou,Zhong-Tai Lin,Shu-Qun Li,Yi-Nan Li,Yang-Kai Fu,Mao-Lin Yan

LIVER CANCERno. 5 (2024): 498-508

引用0浏览0WOS引用

Effect of transcatheter arterial chemoembolization combined with lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: A treatment with Chinese characteristics

Jiayi Wu,Junyi Wu,Shuqun Li,Mengchao Luo,Zhenxin Zeng,Yinan Li,Yangkai Fu,Han Li,Deyi Liu,Xiangye Ou,Zhongtai Lin, Shaoming Wei,Maolin Yan

BIOSCIENCE TRENDS（2024）

引用0浏览0WOS引用

Reply To: "is the TAE Score a Promising Prognostic Predictor for Unresectable Hepatocellular Carcinoma Treated with TACE Plus Lenvatinib with PD‑1 Inhibitors? Further Validation Should Be Performed"

Zhen-Xin Zeng,Jia-Yi Wu,Shao-Wu Zhuang,Mao-Lin Yan

Hepatology internationalno. 5 (2024): 1589-1590

引用0浏览0WOS引用

A New Scoring System for Predicting the Outcome of Hepatocellular Carcinoma Patients Without Microvascular Invasion-a Large-Scale Multicentre Study

Ju-Xian Sun,Zhe Yang,Jia-Yi Wu,Jie Shi,Hong -Ming Yu,Mao -Lin Yan,Shu-Sen Zheng,Shu-Qun Cheng

HPBno. 6 (2024): 741-752

引用0浏览0WOS引用

ASO Author Reflections: Impact of Salvage Surgery in Unresectable Hepatocellular Carcinoma after Conversion Therapy: Should It Be Recommended

Jun-Yi Wu,Jia-Yi Wu,Yang-Kai Fu,Mao-Lin Yan

Annals of surgical oncologyno. 5 (2024): 3100-3101

引用0浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn